TBCB

Across TCGA pan-cancer cohorts, TBCB Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TBCB data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TBCB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBCB expression acts as an unfavorable survival marker.

OV, HNSC, and KIRP are the cancer types where TBCB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.022	0.844	<.001	48	view →
HNSC	OS	Median	All	0.081	0.768	<.001	48	view →
KIRP	OS	Median	All	0.216	0.885	<.001	15	view →
BLCA	OS	Median	III,IV	0.183	0.684	.004	9	view →
SKCM	DFS	Median	All	0.087	0.757	<.001	9	view →
SARC	DFS	Median	All	0.037	0.632	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TBCB–OV (OS)

Open the OV breakdown →